Progress in Pain Control and Liver Disease Programs Spurs Rise in Company's Rating
Source: Streetwise Reports  (7/19/17)
News about progress in two of this biotech's development programs prompted a rating upgrade by analyst Adam Walsh of Stifel Nicolaus & Company. More >

Biotech with Alzheimer's Focus Makes Progress on Several Fronts
Source: Streetwise Reports  (7/18/17)
In its corporate update for Q2/17, a Canada-based biotech targeting neurological disorders including Alzheimer's disease informed investors of advancements in several programs, including designation of a second validated lead compound in development. More >

2017 Small-Cap Biotech Watchlist Update: Up 21% at the End of Q2/17
Source: Streetwise Reports  (7/13/17)
If an investor had purchased an equal dollar amount of each company on The Life Sciences Report's 2017 Small-Cap Biotech Watchlist at the beginning of the year, that portfolio would show a gain of about 21% as of July. This is primarily due to the performance of a handful of companies that have been moving their assets farther down the development pipeline, according to the analysts who follow them. More >

Multifaceted Biotech Company Poised to Begin Trading on Canadian Securities Exchange
Source: Streetwise Reports  (7/11/17)
A Vancouver-based biotech firm that aims to become the first preventative medicine company is expected to commence trading on the Canadian Securities Exchange July 14. More >

Analysts Take Note as Small-Cap Biotech Completes Early Enrollment for Phase 3 Trial
Source: Streetwise Reports  (7/5/17)
With enrollment complete in its Phase 3 trial of a compound that treats post-operative pain, and an infusion of cash from a new partnership with a major pharmaceutical corporation, one analyst has initiated coverage of this California-based company, and another has reiterated his investment thesis.
More >

Coverage Initiated on Synthetic Cannabinoid Bioscience Company, an 'Exciting, Undiscovered Story'
Source: Streetwise Reports  (6/29/17)
Laidlaw & Company initiated coverage with a Buy rating and target price of $18 on a company that is repurposing an approved cannabinoid to fulfill unmet medical needs. More >

With Completion of Offer, Analyst Says This Biotech Stock Could Triple
Source: The Life Sciences Report  (6/28/17)
A Canadian company with its lead drug candidate in a Phase 3 trial recently closed an offering that raised CA$10 million for future research, which has one analyst contemplating the potential for "3x upside." More >

Fast-Growing Pharma Company Prepares to Launch OTC Nasal Spray
Source: The Life Sciences Report  (6/21/17)
A San Diego-based pharmaceutical company that focuses on over-the-counter medications reported strong Q1/17 results and expects to begin marketing a nasal spray by the end of the year. More >

Phase 3 Trial for Inovio's VGX-3100 in Cervical Dysplasia Gets FDA Go-Ahead
Source: The Life Sciences Report  (6/14/17)
Now that the FDA has lifted its clinical hold on Phase 3 study of Inovio Pharmaceutical's immunotherapy for cervical dysplasia, three analysts are making note of what the progress means for both the company and investors. More >

RXi Pharmaceuticals Expands Collaboration with Norwegian Cancer Firm; Gears Up for 2017 Milestones
Source: The Life Sciences Report  (6/7/17)
The potential of RXi Pharmaceuticals' sd-rxRNA technology in the development of cancer immunotherapies has resulted in an extension of its research collaboration with Oslo-based PCI Biotech and captured the attention of two analysts. More >

HIV Vaccine Clinical Study Results in High Immune Response Rates in Healthy Subjects
Source: The Life Sciences Report  (5/31/17)
A clinical study of an HIV vaccine in healthy subjects that found a nearly 100% immune response rate was hailed by a pair of industry analysts. More >

What Is Chen Buying? Gold, Cobalt, Phosphate and Biotech. . .
Source: Chen Lin for Streetwise Reports  (5/25/17)
With the market in flux, Chen Lin of the popular newsletter What Is Chen Buying?, What Is Chen Selling? is hedging his bets with investments in a variety of companies in different sectors. More >

Innovative Company Focused on Women's Health Completes Record-Breaking Quarter
Source: The Life Sciences Report  (5/24/17)
Viveve Medical's Q1/17 results beat expectations, an accomplishment that was welcomed by several industry analysts. More >

Small-Caps Rushing to Fill the NASH Treatment Pipeline
Source: The Life Sciences Report  (5/24/17)
NASH is an epidemic in the U.S., with more than 100 million people believed to be affected. Yet no FDA-approved treatments are available, with the exception of liver transplantation for end-stage disease. In part two of his interview with The Life Sciences Report, Ed Arce, managing director in equity research and senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright, and organizer of the recent inaugural NASH Investor Conference, says that small companies are rushing to fill the pipeline, with numerous compounds in trials. More >

Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug
Source: The Life Sciences Report  (5/17/17)
In light of a decision to pull its application for approval of vosaroxin in the European Union, Sunesis Pharmaceuticals has designated its BTK inhibitor program targeting chronic lymphocytic leukemia as its new lead program. More >

Inovio Moves Forward on Brain Cancer and Cancers Caused by HPV; Zika and Ebola Vaccines Also Advance
Source: The Life Sciences Report  (5/17/17)
Inovio Pharmaceuticals' pipeline of vaccine and immunotherapeutic products is advancing steadily through the phases of development, with a host of milestones anticipated in 2017, including the start of a Phase 3 trial in cervical dysplasia and the initiation of trials with partners in brain cancer and cancers caused by human papillomavirus. In this interview with The Life Sciences Report, Inovio President and CEO, Dr. J. Joseph Kim, walks investors through the promising possibilities, and also provides updates on its vaccines for the Zika, MERS and Ebola viruses. More >

Big Pharma Sets Its Sights on NASH Epidemic
Source: The Life Sciences Report  (5/17/17)
Up to one-third of Americans may have conditions that lead to NASH, yet the disease is far from a household name. Closely linked with obesity, the disease does not become symptomatic until very late stage. Ed Arce, managing director in equity research and a senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright, organized the recent inaugural NASH Investor Conference. In part one of his interview with The Life Sciences Report, Arce discusses the disease, its market potential and how companies large and small are trying to fix the current dearth of treatments. More >

DURECT and Sandoz Ink $293 Million Deal for POSIMIR
Source: The Life Sciences Report  (5/10/17)
DURECT Corp. and Sandoz AG, a division of Novartis, have signed a development and commercialization agreement for the U.S. for POSIMIR. More >

3D Signatures' Platform Taps into the Power of the Genome
Source: The Life Sciences Report  (5/10/17)
How fast is my cancer progressing? Does this treatment present my best option for a cure? These two big questions, which determine outcomes for patients with serious diseases such as Hodgkin's lymphoma, prostate cancer and Alzheimer's disease, are addressed by the platform technology in development by 3D Signatures Inc. In this interview with The Life Sciences Report, 3DS's new Chief Scientific Officer, Dr. Kevin Little, describes the TeloView platform, its utility in the marketplace and what makes it a compelling investment. More >

The ProMIS of an Alzheimer's Cure
Source: The Life Sciences Report  (5/3/17)
With the impacts of Alzheimer's disease on patients, doctors and the health care industry expected to burgeon over the next decade, ProMIS Neurosciences has developed a preclinical program that targets the root cause of the disease, and also offers the potential to get in on an investment with a double bottom line, says Elliot Goldstein, CEO of ProMIS, in this interview with The Life Sciences Report.
More >

Mesoblast Heart Failure Trial Delivers Positive Interim Results
Source: The Life Sciences Report  (5/3/17)
Mesoblast Ltd., an Australia-based regenerative medicine company currently in a Phase 3 clinical trial in chronic heart failure, has received successful interim data, which prompted the Maxim Group to comment favorably on the study's design and progress. More >

Good Epilepsy Data from Zynerba Pharmaceuticals Would Set Stage for Pivotal Trials
Source: The Life Sciences Report  (4/26/17)
Maxim Group noted that data from Zynerba's Phase 2 proof of concept trial will be released in the third quarter; positive data would set the stage for Phase 3 trials. More >

VistaGen's Fast-Acting Antidepressant Targets Multibillion-Dollar Market
Source: The Life Sciences Report  (4/26/17)
Maxim Group recently initiated coverage of VistaGen Therapeutics, citing its progress on development of a fast-acting therapy to treat major depressive disorders. More >

Trial Results Set Up DURECT Corp. for 'Exciting Year'
Source: The Life Sciences Report  (4/26/17)
Positive results in a Phase 1b trial of DURECT Corp.'s candidate for the treatment of nonalcoholic steatohepatitis (NASH), which were presented at the 2017 International Liver Congress, prompted comments from a pair of analysts. More >

2017 Small-Cap Biotech Watchlist Update: Holding Steady in a Volatile Market
Source: The Life Sciences Report  (4/19/17)
The Small-Cap Biotech Watchlist, composed of 20 companies targeting a range of indications including blood cancers and solid tumors, irritable bowel disease and orphan diseases, has posted a modest gain since the first of the year.
More >